Read More Pharma Industry News How the VALIANT Phase 3 data may strengthen EMPAVELI’s nephrology market position Find out how Sobi’s VALIANT Phase 3 data may reshape EMPAVELI’s nephrology market position and what it means for rare kidney disease growth. bySoujanya RaviApril 12, 2026